Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXTOUCH versus NOVOLOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXTOUCH versus NOVOLOG MIX 50 50.
NOVOLOG FLEXTOUCH vs NOVOLOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with rapid onset and short duration of action; binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Subcutaneous injection; typical adult dose is 0.5-1 unit/kg/day divided into multiple doses; for type 1 diabetes, administered 5-10 minutes before meals with a basal insulin; for type 2 diabetes, initial dose 4 units or 0.1-0.2 units/kg with meals.
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
None Documented
None Documented
1.5-2 hours (subcutaneous); terminal elimination half-life: 1.8 hours
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~40%
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Category C
Category C
Insulin Analog
Insulin Analog